Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 

Slides:



Advertisements
Similar presentations
A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,
Advertisements

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Volume 14, Issue 1, Pages (January 2011)
Volume 15, Issue 1, Pages S20-S28 (January 2012)
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis  Klára Kruntorádová, MSc, Jiří Klimeš,
Volume 17, Issue 2, Pages (March 2014)
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
Value in Health Regional Issues
The Development of the Romanian Scorecard HTA System
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil  Ronaldo K.
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
The Process of Privatization of Health Care Provision in Poland
Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F
Ernest Attuquaye Quaye, BPharm, MPH, Edward O
Value in Health Regional Issues
Cost-Effectiveness of Routine Screening for Cardiac Toxicity in Patients Treated with Imatinib in Brazil  Eduardo Gehling Bertoldi, MD, MSc, Milena S.
Value in Health Regional Issues
Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea  Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD,
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.
Value in Health Regional Issues
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala  Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,
Cost-Effectiveness Analysis of Aripiprazole Augmentation Treatment of Patients with Major Depressive Disorder Compared to Olanzapine and Quetiapine Augmentation.
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Cost-Effectiveness of Screening and Treatment for Cervical Cancer in Tanzania: Implications for other Sub-Saharan African Countries  Stephanie Nelson,
Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011  Carlos Castañeda-Orjuela, MD, MSc, Hernando Díaz, PhD, Nelson Alvis-Guzman,
The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems  Randall Winnette, MSc, Victor Zárate, MD, MSc,
Omneya Mohamed, PhD, David H. Kreling, PhD 
Value in Health Regional Issues
Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?  Fei-Li.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective  Bruno Salgado Riveros,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Results of the Inclusion of New Medications in the Obligatory Health System Plan in Colombia, 2012–2013  Jorge Enrique Machado-Alba, PhD, Daniel Torres,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System  Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson,
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Colombian Health System on its Way to Improve Allocation Efficiency—Transition from a Health Sector Reform to the Settlement of an HTA Agency  Nicolás.
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Performance Assessment of the Juaboso District Office of the National Health Insurance Authority  Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia  Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.
Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia  Vlado Jukic, MD, PhD, Miro Jakovljevic, MD, PhD, Igor Filipcic,
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
Victoria I. Ignatyeva, MPH, Johan L
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina  Joaquín.
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia  Joaquín F. Mould-Quevedo, PhD, Magda Vianey Gutiérrez-Ardila, DMD, MSc(c), Jaime Eduardo Ordóñez Molina, MD, PhD, Brett Pinsky, MPH, Nicolás Vargas Zea, MBA, MSc  Value in Health Regional Issues  Volume 5, Pages 48-57 (December 2014) DOI: 10.1016/j.vhri.2014.07.007 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1  (A) Treatment decision tree, primary prevention, and (B) Markov health states, primary prevention and secondary prevention models. CV, cardiovascular; CVD, cardiovascular disease. Value in Health Regional Issues 2014 5, 48-57DOI: (10.1016/j.vhri.2014.07.007) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Discounted total cohort (n = 100) costs for (A) primary and (B) secondary prevention. CVD, cardiovascular disease. Value in Health Regional Issues 2014 5, 48-57DOI: (10.1016/j.vhri.2014.07.007) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Tornado diagrams, primary prevention, for (A) Colombia A20 versus R10 and (B) Brazil A20 versus R10. A20, atorvastatin 20 mg; CVD, cardiovascular disease; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; QALY, quality-adjusted life-year; R10, rosuvastatin 10 mg. Value in Health Regional Issues 2014 5, 48-57DOI: (10.1016/j.vhri.2014.07.007) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 CE acceptability curves, primary prevention, for (A) Colombia A20 versus R10 and (B) Brazil A20 versus R10. A20, atorvastatin 20 mg; CE, cost-effectiveness; QALY, quality-adjusted life-year; R10, rosuvastatin 10 mg. Value in Health Regional Issues 2014 5, 48-57DOI: (10.1016/j.vhri.2014.07.007) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.